Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada’s Drug Pricing Reform Faces Legal Challenge

Executive Summary

Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.

You may also be interested in...



COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms

A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.

Canada To Rethink Controversial Pricing Rules

Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.

Canadian Drug Pricing Reforms Could Lead To Medicine Shortages

Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.

Related Content

Topics

UsernamePublicRestriction

Register

PS140839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel